Galectin-9 ameliorates anti-GBM glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice

Qian Zhang, Hong Luan, Le Wang, Fan He, Huan Zhou, Xiaoli Xu, Xingai Li, Qing Xu, Toshiro Niki, Mitsuomi Hirashima, Gang Xu, Yongman Lv, Yuan JinAmerican 2014 · DOI

TL;DR

This study demonstrates that Galectin-9 (Gal-9) can significantly ameliorate anti-GBM glomerulonephritis (anti-GBM GN) in mice. By inhibiting the pro-inflammatory Th1 and Th17 immune responses and simultaneously promoting a beneficial Th2 response, Gal-9 offers a promising therapeutic avenue for this aggressive autoimmune kidney disease.

What Problem Does This Paper Address?

Anti-glomerular basement membrane (anti-GBM) glomerulonephritis is a severe autoimmune condition characterized by rapid kidney function decline and the formation of glomerular crescents. This disease is primarily driven by T helper 1 (Th1) and T helper 17 (Th17) immune cells, which are known to promote inflammation and tissue damage in the kidneys. While the role of these T cell subsets is established, the precise mechanisms by which they contribute to anti-GBM GN and how they might be therapeutically targeted remain areas of active investigation. Specifically, the authors sought to understand if Galectin-9, a molecule known to interact with the Tim-3 receptor on T cells and induce apoptosis, could modulate these Th1 and Th17 responses and protect against kidney injury in this disease model.

Methods

The researchers utilized a mouse model of anti-GBM glomerulonephritis, induced by administering rabbit anti-mouse GBM antiserum. Galectin-9 was administered to these mice for seven days. Key techniques employed included:

  • Histology and Immunofluorescence: To assess kidney damage (crescent formation, tubular injury, glomerular sclerosis) and the deposition of immune molecules (rabbit and mouse IgG).
  • Renal Function Tests: Measuring serum creatinine and urine albumin-to-creatinine ratio to evaluate kidney function.
  • Flow Cytometry: To analyze the populations of different T cell subsets (CD4+Tim-3+, Th1 (IFN-γ+), Th2 (IL-4+), and Th17 (IL-17A+)) in the spleen and kidneys.
  • Real-time PCR: To quantify the mRNA expression of pro-inflammatory cytokines and chemokines (e.g., IFN-γ, IL-17A, CCL-2, CXCL-9) in kidney tissue.
  • Western Blotting: To examine the expression of key transcription factors involved in T cell differentiation (T-bet for Th1, GATA-3 for Th2, RORγt for Th17).
  • In vitro T cell culture: Purified CD4+ T cells were stimulated and treated with Gal-9 to investigate its direct effects on T cell apoptosis and differentiation, with and without a-lactose (a Gal-9 binding inhibitor) to assess Tim-3 dependency.

Datasets

Not discussed in the paper. The study relies on experimental data generated from mouse models and in vitro cell cultures.

Key Insights and Ideas

  • Gal-9 as a Double-Edged Sword: Gal-9 doesn't just suppress the "bad" immune cells (Th1/Th17); it also appears to actively promote the "good" ones (Th2) in the kidney. This dual action is crucial for its protective effect.
  • Tim-3 Dependency is Key for Inhibition: The study strongly suggests that Gal-9's ability to inhibit Th1 and Th17 cell differentiation and induce apoptosis is mediated through its interaction with the Tim-3 receptor. This was demonstrated by the reversal of these effects when a-lactose was used to block Gal-9 binding to Tim-3.
  • Kidney-Specific Th2 Enhancement: While Gal-9's impact on Th1 and Th17 was observed in both spleen and kidneys, the enhancement of Th2 responses seemed more pronounced within the kidney itself, suggesting a localized protective mechanism.
  • Chemokine Regulation: Gal-9's ability to downregulate key chemokines (like CCL-20, CXCL-9, CXCL-10) in the kidney likely contributes to reduced immune cell infiltration, a critical step in preventing further damage.

Key Results

  • Renal Protection: Gal-9 treatment significantly slowed the deterioration of renal function, reduced proteinuria, and ameliorated structural kidney damage, including decreased crescent formation and interstitial injury.
  • Reduced Th1/Th17 Infiltration: The number of Th1 (IFN-γ+) and Th17 (IL-17A+) cells in both the spleen and kidneys of Gal-9-treated mice was significantly reduced compared to untreated anti-GBM GN mice.
  • Increased Th2 Response: Gal-9 treatment led to an increased proportion of Th2 (IL-4+) cells in the kidneys.
  • Cytokine Modulation: Blood levels of pro-inflammatory cytokines IFN-γ and IL-17A were reduced in Gal-9-treated mice, while IL-4 mRNA expression in the kidneys was increased.
  • Transcription Factor Regulation: In vitro, Gal-9 suppressed the expression of T-bet and RORγt (Th1 and Th17 transcription factors) but not GATA-3 (Th2 transcription factor), and conversely, GATA-3 expression was increased.

Limitations and Future Work

  • Direct vs. Indirect Th2 Enhancement: The authors acknowledge a limitation in definitively determining whether the enhanced Th2 response in the kidneys is a direct effect of Gal-9 or a secondary consequence of Th1/Th17 inhibition. Future studies could explore this further.
  • Clinical Translation: While promising, this study was conducted in a mouse model. Further research is needed to assess the efficacy and safety of Gal-9 in human clinical trials for anti-GBM GN.
  • Mechanism of Th2 Regulation: The study suggests Gal-9's regulation of Th2 cells is cell-contact independent. Further investigation into the specific pathways involved in this enhancement would be valuable.
  • Long-term Effects: The study focused on a 7-day treatment period. Investigating the long-term effects of Gal-9 administration on disease progression and remission would be beneficial.

Summary updated

Abstract

Antiglomerular basement membrane glomerulonephritis (anti-GBM GN) is a Th1- and Th17-predominant autoimmune disease. Galectin-9 (Gal-9), identified as the ligand of Tim-3, functions in diverse biological processes and leads to the apoptosis of CD4(+)Tim-3(+) T cells. It is still unclear how Gal-9 regulates the functions of Th1 and Th17 cells and prevents renal injury in anti-GBM GN. In this study, Gal-9 was administered to anti-GBM GN mice for 7 days. We found that Gal-9 retarded the increase of Scr, ameliorated renal tubular injury, and reduced the formation of crescents. The infiltration of Th1 and Th17 cells into the spleen and kidneys significantly decreased in Gal-9-treated nephritic mice. The reduced infiltration of Th1 and Th17 cells might be associated with the downregulation of CCL-20, CXCL-9, and CXCL-10 mRNAs in the kidney. In parallel, the blood levels of IFN-γ and IL-17A declined in Gal-9-treated nephritic mice at days 21 and 28. In addition, an enhanced Th2 cell-mediated immune response was observed in the kidneys of nephritic mice after a 7-day injection of Gal-9. In conclusion, the protective role of Gal-9 in anti-GBM GN is associated with the inhibition of Th1 and Th17 cell-mediated immune responses and enhanced Th2 immunity in the kidney.
BibTeX
@inproceedings{zhang2014galectin,
  author = {Qian Zhang and Hong Luan and Le Wang and Fan He and Huan Zhou and Xiaoli Xu and Xingai Li and Qing Xu and Toshiro Niki and Mitsuomi Hirashima and Gang Xu and Yongman Lv and Yuan Jin},
  title = {{Galectin-9 ameliorates anti-GBM glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice}},
  booktitle = {American},
  year = {2014},
  doi = {10.1152/ajprenal.00294.2013},
}
Figure